Intellia Therapeutics (NTLA) Competitors $12.06 +0.23 (+1.94%) Closing price 04:00 PM EasternExtended Trading$12.04 -0.02 (-0.12%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, PCVX, CYTK, MTSR, ADMA, KRYS, AKRO, and RNAShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Vaxcyte Cytokinetics Metsera ADMA Biologics Krystal Biotech Akero Therapeutics Avidity Biosciences Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Do institutionals & insiders have more ownership in NTLA or BEAM? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, NTLA or BEAM? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M21.58-$519.02M-$5.23-2.31Beam Therapeutics$63.52M32.85-$376.74M-$4.61-4.50 Is NTLA or BEAM more profitable? Beam Therapeutics has a net margin of -609.24% compared to Intellia Therapeutics' net margin of -1,154.10%. Beam Therapeutics' return on equity of -44.24% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-1,154.10% -56.06% -44.25% Beam Therapeutics -609.24%-44.24%-30.97% Which has more risk and volatility, NTLA or BEAM? Intellia Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Do analysts prefer NTLA or BEAM? Intellia Therapeutics presently has a consensus price target of $33.37, suggesting a potential upside of 176.69%. Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 134.94%. Given Intellia Therapeutics' higher probable upside, research analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media favor NTLA or BEAM? In the previous week, Beam Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.48 beat Beam Therapeutics' score of 0.47 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryBeam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23B$2.96B$5.54B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-2.3119.7528.0119.82Price / Sales21.58299.50432.7298.44Price / CashN/A42.5936.1658.27Price / Book1.417.678.125.65Net Income-$519.02M-$55.28M$3.25B$257.91M7 Day Performance4.60%2.50%0.97%2.09%1 Month Performance25.63%11.70%7.36%11.13%1 Year Performance-53.78%4.89%31.31%18.40% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.4072 of 5 stars$12.06+1.9%$33.37+176.7%-56.8%$1.23B$57.88M-2.31600Gap UpBEAMBeam Therapeutics2.0658 of 5 stars$21.17+0.0%$48.75+130.3%-24.1%$2.13B$63.52M-4.59510Gap UpCRSPCRISPR Therapeutics2.69 of 5 stars$56.42-0.7%$71.75+27.2%-8.9%$4.87B$37.31M-12.48460Insider TradeAnalyst RevisionGap UpEDITEditas Medicine4.0918 of 5 stars$2.85-1.0%$4.70+64.9%-52.3%$238.57M$32.31M-0.94230News CoveragePositive NewsPCVXVaxcyte1.801 of 5 stars$36.38+1.3%$136.50+275.2%-54.1%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.0425 of 5 stars$38.58+4.2%$70.92+83.8%-31.5%$4.61B$18.47M-7.29250Insider TradeMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081ADMAADMA Biologics3.8794 of 5 stars$18.68+0.9%$27.67+48.1%+32.4%$4.46B$426.45M21.98530Positive NewsKRYSKrystal Biotech4.5474 of 5 stars$150.41+1.5%$213.75+42.1%-27.6%$4.35B$290.52M36.16210Insider TradeAnalyst RevisionAKROAkero Therapeutics3.6777 of 5 stars$52.73+2.2%$82.50+56.5%+100.6%$4.20BN/A-27.0430Positive NewsInsider TradeRNAAvidity Biosciences2.1866 of 5 stars$33.57+6.7%$66.35+97.7%-24.6%$4.05B$8.93M-11.19190High Trading Volume Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Vaxcyte Alternatives Cytokinetics Alternatives Metsera Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Akero Therapeutics Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.